A patient with severe aortic stenosis may report feeling well after quietly giving up stairs or longer walks. Asking what activities have changed is a useful first step. When feasible, supervised exercise testing can help determine whether the patient is genuinely asymptomatic. For patients with severe high-gradient disease, a left ventricular ejection fraction (LVEF) of at least 50% and low procedural risk, the timing of valve replacement is now worth discussing before symptoms appear. [1] [2]
Which outcomes changed in EARLY TAVR?
The trial randomized 901 patients with asymptomatic severe aortic stenosis to early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. Their mean age was about 76, and most had low surgical risk. Over a median 3.8 years, death, stroke or an unplanned cardiovascular hospitalization occurred in 26.8% with early TAVR and 45.3% with surveillance (hazard ratio 0.50, 95% confidence interval 0.40–0.63). [1]
Unplanned cardiovascular hospitalization accounted for the largest difference, at 20.9% versus 41.7%. Mortality was 8.4% versus 9.2%. During follow-up, 87% of the surveillance group eventually underwent valve replacement. For many participants, the practical question was when to intervene. [1]
Reading the 2026 analysis in clinic
In a November 2026 analysis of the same participants, 29.4% already met at least one Class II indication for replacement under the 2020 US guidelines. Investigators found a consistent treatment effect in patients with and without these features. This subgroup analysis draws on the original trial population and supplies no independent comparison in younger patients. [3]
The 2025 European guidelines advise considering early intervention as an option for asymptomatic, severe high-gradient stenosis when LVEF is at least 50% and procedural risk is low. An otherwise unexplained LVEF below 50% is a separate indication for intervention. A Heart Team can assess anatomy, age, expected longevity and the patient’s preference when discussing surgery, TAVR or surveillance. A younger adult contemplating a lifetime of valve care faces durability questions beyond this trial’s follow-up. [1] [2]
What to take into practice
If surveillance is chosen, agree on a follow-up interval and a direct route back to the valve clinic. European guidance calls for reassessment at least every six months and earlier review if symptoms develop. [2]
Browse the MedBay catalogue for Cardiology
Sources
Evidence checked on 21 November 2026.
[1] Généreux et al. EARLY TAVR randomized trial, New England Journal of Medicine (2024-10-28).
[2] ESC/EACTS Task Force. 2025 Guidelines for the management of valvular heart disease, European Heart Journal (2025-08-29).
[3] EARLY TAVR investigators. Guideline-directed indications for valve replacement, JACC: Cardiovascular Interventions (2026-11-09).